Free Trial
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Price, News & Analysis

$3.84
-0.22 (-5.42%)
(As of 07/15/2024 ET)
Today's Range
$3.82
$4.07
50-Day Range
$2.93
$4.36
52-Week Range
$2.41
$7.22
Volume
98,740 shs
Average Volume
190,780 shs
Market Capitalization
$115.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Relmada Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
251.6% Upside
$13.50 Price Target
Short Interest
Healthy
3.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
0.54mentions of Relmada Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.04) to ($2.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.69 out of 5 stars

Medical Sector

253rd out of 913 stocks

Pharmaceutical Preparations Industry

110th out of 432 stocks

RLMD stock logo

About Relmada Therapeutics Stock (NASDAQ:RLMD)

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

RLMD Stock Price History

RLMD Stock News Headlines

Relmada Therapeutics (NASDAQ:RLMD) Shares Up 5.6%
Financial Nostradamus Issues Chilling Warning About America
I recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America.
7 Penny Biotech Stocks to Triple Your Investment
Financial Nostradamus Issues Chilling Warning About America
I recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America.
Q1 2024 Relmada Therapeutics Inc Earnings Call
RELMADA THERAPEUT.DL-,001 (4E2.F)
See More Headlines
Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/15/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLMD
Fax
N/A
Employees
20
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$25.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+243.5%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-98,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.84 per share

Miscellaneous

Free Float
24,743,000
Market Cap
$118.57 million
Optionable
Optionable
Beta
0.50

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Sergio Traversa M.B.A. (Age 64)
    Pharm.D., CEO & Director
    Comp: $1.79M
  • Mr. Maged S. Shenouda M.B.A. (Age 60)
    R.Ph., Chief Financial Officer
    Comp: $1.01M
  • Mr. Charles S. Ence CPA (Age 59)
    M.B.A., Chief Accounting & Compliance Officer
    Comp: $995.03k
  • Dr. Paolo Manfredi M.D. (Age 62)
    Ph.D., Chief Scientific Officer
  • Ms. Gina DiGuglielmo
    VP & Head of Clinical Operations
  • Dr. Marco Pappagallo M.D. (Age 65)
    Chief Clinical Officer
  • Mr. John Hixon
    Head of Commercial
  • Dr. Andrew Cutler
    Senior Clinical Development Advisor
  • Dr. Richard M. Mangano (Age 74)
    Consultant

RLMD Stock Analysis - Frequently Asked Questions

How have RLMD shares performed this year?

Relmada Therapeutics' stock was trading at $4.14 at the beginning of the year. Since then, RLMD stock has decreased by 7.2% and is now trading at $3.84.
View the best growth stocks for 2024 here
.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.18.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLMD) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners